Kornimate/medical-research-clean huggingface dataset:
pre-hospital care profile of road traffic injury victims- kerala

Conditions: Trauma; Road (Traffic) Accident [RTA] Nos

Summary: selection of appropriate strategies and correct policy-making in these conditions may lead to decreased rates of death due to rti.there is a lack of research on the effectiveness of pre-hospital care in kerala. this study aimed to describe the prehospital care of rti victims presenting to the emergency department in jubilee mission medical college and research institute, thrissur.

management of trauma is a neglected field in developing nations.road traffic injuries (rti) cause around 1.35 million deaths worldwide annually according to the statistics of world health organization (who) and in india 150000 death per year. an overwhelming proportion of these deaths occur before patients even reach the hospital. two third (60.7%) of the accident victims belonged to the age range of 15 to 44 years. this indicates that active and productive age people are the one affected by road traffic accidents related injuries in turn adding to higher economic loss to the country. lack of medical attention is attributed to nearly 30 per cent of deaths at site and 80 per cent of the remaining patients died within an hour of injury (golden hour). most of these deaths are due to airway management failure, respiratory failure or continuing hemorrhage that are preventable causes with appropriate prehospital and subsequent hospital emergency care. mortality due to rti is increasing, especially in low and middle income countries (lmic). there is a lack of research on the effectiveness of pre-hospital care in india. selection of appropriate strategies and correct policy-making in these conditions may lead to decreased rates of death due to rti in several countries.this study aimed to describe the prehospital care of rti victims presenting to the emergency department (ed) in jubilee mission medical college and research institute, thrissur.

Eligibility criteria:
inclusion criteria: all road traffic injury (rti) patients presenting to ed within 24 hours of injury exclusion criteria: individual's not consenting to be part of the study or withdrawing consent later on cases where pre-hospital care provider could not be traced or where reliable patient data could not be collected even after repeated interview.
objective systolic function recuperation assessed by echocardiography

Conditions: Myocardial Infarction; Left Ventricular Systolic Dysfunction; Anterior Akinesis; Apical Akinesis

Summary: the purpose of this study is to evaluate left ventricular systolic ejection fraction and anterior or apical akinesis 1 month and 3 months after a myocardial infarction treated with primary pci to determine whether improvement at 1 month differs from improvement at 3 months.


Eligibility criteria:
inclusion criteria: * older than 18 years old * st elevation myocardial infarction treated with primary pci * anterior or apical akinesis and left ventricular ejection fraction ≤ 45% on early echocardiography (48hours - 7 days post myocardial infarction) * initial ecg showing at least 1 mm st elevation in 2 leads corresponding to the same vascular territory exclusion criteria: * known left ventricular systolic dysfunction before myocardial infarction * left bundle branch block * vital prognosis less than 6 months * cardiogenic shock * rescue pci * sub-optimal echocardiographic imaging (contrast use is allowed) * significant valvular heart disease (moderate or severe) * surgical revascularization * pregnancy or breastfeeding * incapacity to provide informed consent

Keywords: echocardiography st elevation myocardial infarction heart failure coronary artery disease cardiovascular diseases
prostate biomarkers in men consuming tomato products

Conditions: Prostate Cancer

Summary: prostate biomarkers in men consuming tomato products

participants completed a minimum week-long washout period without consumption of tomato products prior to randomization to one of four dietary interventions. men were randomized to one of the following dietary interventions: a controlled low lycopene diet (≤ 5 mg/d from foods), daily prego® spaghetti sauce, daily v8® vegetable juice, or daily campbell's® tomato soup. each of the tomato products provided between 25 and 35 mg lycopene per day. in order to provide this dietary intervention in typical serving sizes in the context of a usual diet but devoid of other tomato sources, participants kept daily logs documenting compliance with the intervention product and a tomato-restricted diet from enrollment to the day of surgery (\~3 weeks). study participants were asked to complete an abbreviated dietary history questionnaire (to establish typical consumption patterns of various tomato products) and two separate 3-day diet food records, once during the washout and once during the intervention period. blood and 24-hour urine samples were obtained at two time points, after the one-week washout phase and at the end of the dietary intervention period. fresh prostate samples were obtained at time of surgery.

Eligibility criteria:
inclusion criteria: to be included in this study, men must: * have biopsy-proven, clinically localized adenocarcinoma of the prostate based on standard presurgical staging studies * have chosen to undergo a radical prostatectomy for treatment of their disease after the medical team has presented all possible treatment options * have kidney and liver enzymes, cbc, and pt/ptt/inr within normal limits * agree to sign consent form prior to enrollment in the study exclusion criteria: men may not participate in this if they: * are currently taking lycopene or "alternative" dietary supplements * have a history of digestive or malabsorptive disorders, metabolic enzyme deficiencies, or other disorders requiring special dietary modifications (controlled type ii diabetes mellitus was allowed)
bortezomib consolidation trial

Conditions: Multiple Myeloma

Summary: the aim of this trial is to determine whether bortezomib improves response and delays progression for multiple myeloma patients after high dose therapy and autologous stem cell transplant. it will also assess the effect of bortezomib treatment on patient bone health.


Eligibility criteria:
inclusion criteria: * mm patients who have received high dose melphalan with asct 3-4 months prior to registration and have not progressed * age 18 - 70 years * life expectancy \> 6 months * written informed consent * creatinine \< 400µmol/l * bilirubin \< 3x upper limit of normal * who performance status 0-2 * contraceptive precautions where appropriate exclusion criteria: * received bortezomib previously * on, or planned for, steroid therapy * poor performance status (ecog ≥ 3) * disease progression at any stage * past history of polio, cord compression or other neurological condition resulting in persisting neurological deficit ≥ grade 2 * severe hepatic impairment, indicated by bilirubin ≥ 3x upper limit of normal, or ast \> 2.5x upper limit of normal * pregnant or lactating women * allergic reaction attributable to bortezomib or to compounds containing boron or mannitol * severe cardiovascular disease * history of acute infiltrative pulmonary or pericardial disease * history of hypotension or has decreased blood pressure * peripheral neuropathy ≥ grade 2, or neuropathic pain * serious medical or psychiatric illness likely to interfere with participation in this clinical study * received any drugs or agents that inhibit or induce cyp2c19 or cyp3a4 within 14 days before the first dose of bortezomib * need for therapy with concomitant cyp 3a4 or cyp2c19 inhibitors * have received an experimental drug or used an experimental medical device within 4 weeks before the planned start of treatment

Keywords: mm hdt asct consolidation bortezomib
glycemic effect of colesevelam hcl (welchol) in patients with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to obtain continuous glucose monitoring (cgm) data from individuals taking welchol compared to placebo. the cgm data will determine the effect on glucose control of adding welchol to an anti-diabetic medication regimen.

to understand the effect of the addition of colesevelam hcl to oral agent therapy in individuals with type 2 diabetes on glycemic control by utilizing a novel technology, continuous glucose monitoring with ambulatory glucose profile analysis. to date there are no studies of this compound that have employed continuous glucose monitoring (cgm) with ambulatory glucose profile (agp) analysis to obtain data that will detail the diurnal glucose patterns associated with this therapy. we plan to employ cgm at critical points throughout the study. agp analysis will enable rapid assessment of the clinical status of the subject. using statistically stable estimates of hourly values represented by five percentile curves agp depicts glucose exposure, variability and stability. previously, we have used agp analysis to characterize glucose perturbations in individuals ranging from normal glucose tolerance to overt type 2 diabetes.

Eligibility criteria:
inclusion criteria: * male or female subjects ≥18 and ≤75 years of age * clinical diagnosis of type 2 diabetes * currently treated with metformin, a sulfonylurea, or combination metformin/sulfonylurea; stable dose for ≥3 months * hba1c of 7.0-9.0% inclusive * if taking lipid lowering medications, stable dose for \>30 days exclusion criteria: * taken oral or injected prednisone or cortisone medications in the previous 30 days. (topical or inhaled steroids will not be considered excluded medications.) * current use of insulin or tzd's, or incretins * ldl \<70 mg/dl * serum triglycerides \>500 mg/dl * history of hypertriglyceridemia-induced pancreatitis * history of gastrointestinal disorder such as dysphagia, swallowing disorder, intestinal motility disorder or prior bowel obstruction * history or presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the investigator would compromise the subject's safety or successful participation in the study * unable to follow the study protocol * unable to speak, read and write in english * pregnant, planning to become pregnant, breast feeding
quality of life in chinese working and school age population with mdd

Conditions: Major Depressive Disorder; Remission

Summary: major depressive disorder (mdd) is a common mental illness with high prevalence and global burden. previous studies revealed that over 70% patients in remission still had decreased quality of life, severe function impairment, low positive mental health score and poor coping ability. however, few studies focus on working and school age patients with mdd. a gbd survey showed that over 40% mdd patients are 15-50 years old. therefore, we initiate the present multi-center cross-sectional survey to investigate the associations between clinical symptoms, cognitive function, occupational/study ability, and quality of life in chinese working and school age population with mdd who are in remission.

this is a multi-center cross-sectional study. patients with mdd who received medication treatment and achieved remission for at least 8 weeks will be enrolled. for all the participants, demographic information will be collected; clinical symptoms, cognitive function, occupational/study ability, and quality of life will be evaluated by using 17-items hamd, phq-9, hama, psqi, shaps, hcl-32, sds, leaps, qol-6, pfq and thinc-it toolkit.

Eligibility criteria:
inclusion criteria: * out-patients; * men or women aged between 16 and 50, with junior high school education or above; * according to medical history, patients should be diagnosed with major depressive episode by two or above psychiatric doctors based on icd-10 criteria; * according to assessment, patients should meet the dsm-5 criteria for mdd when in past episodes; * patients received stable ant-depression medication treatment for at least 8 weeks before enrolment; * 17-item hamd total score ≤ 7; * willing to participate in this study, and sign an informed consent. exclusion criteria: * hcl-32 total score \< 12; * diagnosed with bipolar disorder; * suffering from some serious physical diseases (e.g. moderate or severe brain injury, central nervous system diseases, or other unstable physical condition affecting the whole body) adversely affects the performance on neuropsychological test or rating scales; * received ect in the past 6 months.

Keywords: cognitive function social function quality of life working and school age population
pilot study on the feasibility of systematic hepatitis c screening of hospitalized patients

Conditions: Hepatitis C

Summary: the ministry of health has set the target of eradicating hepatitis c (hcv) in france by 2025. the goal is to validate the feasibility and value of conducting routine hcv screening in hospitalized patients.

the number of undetected hcv-infected persons has been extrapolated to 75,000 according to the results of a 2014 study. screening efforts have been set up in groups of people said to be at high viral risk: drug users, prisoners, precarious persons or migrants from highly endemic countries. nevertheless, the concept of universal screening has not yet been adopted by the guardians and the ministry. it is in this context that "hepatitis free hospital" projects have been carried out in several french cities such as nice, nancy and marseille. the aim of the hospi-vhc study is to evaluate the feasibility and efficiency of systematic hcv screening in all medical and surgical departments of 4 national association of hepato-gastroenterologists of general hospitals (angh) hospitals. this pilot project is part of a public health screening program. it will evaluate the interest and usefulness of implementing universal screening in hospitalized patients without taking into account the existence of viral risk factors. this study will also make it possible to evaluate the implementation of a dedicated care pathway: number of patients screened, number of patients referred for consultation and number of patients accepting the consultation.

Eligibility criteria:
inclusion criteria: * patient over 18 years of age * hospitalized during the study period * non-opposition for participation in the protocol exclusion criteria: * patients under 18 years of age * outpatient, long-stay, maternity and intensive care inpatients * patients refusing blood collection * patient may not understand the information sheet * patient under guardianship
study assessing the effects on endometrium and breast of isoflavone in post menopausal women

Conditions: Postmenopause

Summary: the main objective of this study is to determine the effects on the endometrium and breast of 70 mg daily dose of isoflavones.

this is an international multicentre open study, assessing the innocuity on breast and endometrium of a 70 mg daily dose of isoflavones standardized extract (phytosoya). this study follows the european guidelines :one-year treatment duration, biopsy and mammography performed at the beginning and at the end of the trial, recruitment of enough subjects in order to have 300 patients with an evaluable biopsy after one year of treatment. after 3 weeks of screening phase, the patients will be taken phytosoya during 52 weeks. at the end of the first year of treatment, an endometrial biopsy, an endovaginal ultrasonography, a mammography, breast ultrasounds, a clinical examination and a biological assessment will be performed. in addition, it will be proposed to patients to continue treatment during 2 additional years. at the end of the third year,the same examinations will be performed.

Eligibility criteria:
inclusion criteria: * not hysterectomised women * post menopausal (at least 2 years) * fsh superior to 30 ui/l and oestradiol inferior to 35 ng/ml * presenting with hot flushes (but not incapacitating) or climacteric symptoms exclusion criteria: * history of endometrial hyperplasia * known hormono-dependent malignant tumours * bmi superior to 30 kg/m2 * uncontrolled arterial hypertension * known renal or liver insufficiency * recent or evolutive thromboembolic disease * unexplained bleeding, endometrial polyps, submucous myomas, active endometriosis, ovarian cyst superior to 30 mm * local hormonal treatment, raloxifene,tibolone within the 3 months before v1 and during the study * hrt and dhea within the 3 months before v2 and during the study * isoflavones within the 2 months before v2 and during the study * clonidine, beta-alanine, veralipride within 1 month before v1 and during the study.

Keywords: menopause isoflavone endometrial safety breast innocuity assessment hot flushes
neuroimaging and end stage renal disease

Conditions: End Stage Renal Disease

Summary: brain impairment is one of the common complications of end-stage renal disease (esrd). the patients always present with various cerebrovascular diseases, cognitive impairment and sensorimotor abnormalities, with morbidity over 40%. however, the risk factors and the neural mechanisms of brain injury in esrd is still unclear. identifying the risk factors and finding objective and reliable biomarkers of brain impairment in the process of esrd is an important clinical problem. at the same time, to find the neural mechanisms of brain damage in esrd is a serious scientific problem. neuroimaging techniques based on multi-modal magnetic resonance image (mri) can detect the structural and functional brain abnormalities objectively and sensitively, especially for those without obvious clinical symptoms. through the deep analysis of brain mri data, it is helpful for studying the neural mechanisms of brain damage in esrd in the perspective from brain science. in addition, the accumulation of uremic toxins is supposed to play an essential role in the brain impairment of esrd. the metabolomics is a useful method in detecting the uremic toxins with different molecular weights. in this study, the investigators will collect the brain mri, serum metabolomics and cognitive assessment data before the dialysis initiation, and then will make prospective longitudinal observation of changes of brain impairment during the dialysis. thus, combining analysis of neuroimaging and metabolomics will provide more information for finding the risk factors and imaging diagnostic markers of brain impairment in esrd. it will also helpful for explaining the underlying mechanisms of brain impairment in esrd, providing an objective basis for clinical diagnosis and prediction of the prognosis.


Eligibility criteria:
inclusion criteria: * diagnosis with end stage renal disease before dialysis initiation * chronic renal failure * chronic renal failure * 18-55 years old * right handedness exclusion criteria: * concurrent severe infection * with other severe diseases * history of central nervous system diseases, such as mental disorder, degenerative diseases of central nervous system, tumors, trauma, etc. * history of alcohol dependence and drug abuse * history of brain operation * loss of vision or hearing * psychotropic medication in three months * contraindication of mri examination, such as metal implants and claustrophobia, and other reasons that cannot cooperate with mri examination * cerebrovascular diseases which can be detected from conventional mr images, including the size of cerebral hemorrhage over 10 mm, infarction over 20 mm, subarachnoid hemorrhage, subdural hemorrhage and extradural hemorrhage.
ring versus suture annuloplasty for functional tricuspid regurgitation in rheumatic mitral valve diseases

Conditions: Functional Tricuspid Regurgitation

Summary: this study aims to compare whether de vega's suture annuloplasty is equally effective in reducing the progression of functional tricuspid regurgitation as that claimed for ring annuloplasty in rheumatic heart disease patients with concurrent mitral valve replacement.

functional tricuspid regurgitation (ftr) occurs due to annular dilatation in association with left sided valve disease and is more commonly seen than primary pathology in patients with rheumatic mitral valve disease. ftr occurs due to increased right ventricle after load that leads to either dilatation or geometric deformation of tricuspid annulus. if left untreated, ftr may worsen and increase morbidity and mortality.

Eligibility criteria:
inclusion criteria: * the participants will be all patients between 15 to 75 years of age group diagnosed as a case of rheumatic mitral valve disease with moderate to severe functional tricuspid regurgitation. exclusion criteria: * patient with organic tricuspid valve (tv) lesion diagnosed in echocardiography * patient with ftr requiring mitral valve repair * patient with ftr requiring concomitant aortic valve replacement * patient with ftr secondary to pathology other than mitral valve disease

Keywords: ring annuloplasty suture annuloplasty functional tricuspid regurgitation
the effect of frequency and duration of breaks in sitting time on metabolic cardiovascular risk factors

Conditions: Sedentary Lifestyle; Overweight and Obesity; Metabolic Disease

Summary: the primary aim of this study is to investigate the acute effect of the frequency and duration of breaks in sitting time on the metabolic risk factor profile.

fifteen (n=15) sedentary adult overweight males will be included in the study. all participants will undergo the four interventions in a randomized cross-over design. wash out between intervention will be minimum four days. control (con): participants will be sedentary. sedentary time will be spent sitting in a chair, restricted to sedentary behaviors (working on a computer, reading, watching tv, etc.), with a target met below 1.5 (i.e. 1.5 times ree). participants will only be allowed to stand or walk to go to the toilet. breaker: participants will be breaking up prolonged sitting with 2 min intervals of low intensity walking. intermediate: participants will be breaking up prolonged sitting with 6 min intervals of low intensity walking prolonger: participants will be breaking up prolonged sitting with 12 min intervals of low intensity walking all interventions will be matched for total physical activity as well as sitting. thus, we aim for the active interventions to be iso-caloric.

Eligibility criteria:
inclusion criteria: * males, age 20-50 years, waist-to-height ratio ≥ 0.5 and/or waist circumference ≥ 102 cm. exclusion criteria: * clinically diagnosed diabetes, uncontrolled hypertension, use of glucose- and/or lipid-lowering medication, smoking, evidence of thyroid, liver, lung, heart or kidney disease, non-sedentary occupation, and vo2max levels above the considered average fitness according to age (shvartz \& reibold 1990), contraindications to increased levels of physical activity.

Keywords: exercise breaking prolonged sitting physical activity